The IV therapy market in Arizona has expanded faster than the compliance infrastructure around it. A new IV lounge opens, a medical director is named, a one-page standing order is drafted, and the practice starts seeing patients. The problem is that a one-page standing order covering a twelve-drip menu is not sufficient documentation — and when something goes wrong, "we had a medical director" is not a defense.
This guide is written for two audiences: IV lounge owners and operators who want to know exactly what compliance documentation they need, and medical directors (or prospective medical directors) who want to understand what "directing" an IV practice actually requires. The two questions are connected — a director who doesn't know what protocols to write can't protect a practice any more than a practice that doesn't know what to ask for.
We cover: (1) standing orders by drip category, (2) IV access and site care protocol, (3) patient screening requirements, (4) vital signs and pre-infusion assessment, (5) adverse event response protocols, (6) emergency procedures, (7) scope of practice boundaries, and (8) the medical director relationship structure. Each section identifies what the document must contain — not just that it must exist.
Why Generic Standing Orders Fail Inspections — and Patients
The most common protocol failure in IV lounges is specificity. A standing order that says "administer Myers' Cocktail as requested" leaves every clinical decision to the nurse: which patients qualify, what to do if the patient has a kidney condition, what rate to run the drip, what to watch for, and what to do if the patient feels unwell mid-infusion. Each of those unstated decisions is a liability event waiting for a trigger.
A valid standing order for an IV drip must specify the clinical context precisely enough that any competent RN can administer the drip correctly without asking the director. If the nurse has to call the director to know whether a patient qualifies, the standing order is inadequate. The director's role is to write protocols thorough enough that qualified nurses can operate within them safely — not to be on call for every clinical judgment call.
There is also a secondary failure mode: vague protocols that are never reviewed. A standing order signed in 2021 for a formulation that has since been changed — different concentrations, different add-ons, different patient population — is not a valid order for the current clinical situation. Protocol review is not a one-time event. Medical directors should review and re-execute all standing orders at minimum annually, and whenever the practice's formulation menu or patient population changes.
Protocol 1: Standing Orders by Drip Type
Every distinct formulation on your menu requires its own standing order. "Myers-adjacent" or "custom drip" are not order categories — they are documentation gaps. If you offer ten drip options, you need ten individual standing orders. If you add a new drip, a new standing order must be executed before the first patient receives it.
Below are the standing order requirements for the most common IV therapy categories. Every practice's formulations differ — these are the categories and key clinical considerations, not universal protocols.
Hydration drips feel basic but are the most common cause of fluid overload events in IV lounges. The standing order must define the patient population clearly — "anyone who asks" is not a valid indication.
High-dose vitamin C is one of the highest-risk IV therapy offerings from a compliance standpoint. Practices offering doses above 15g without G6PD screening documentation are operating outside standard of care.
NAD+ is the category where "the nurse called the director from the drip chair" events happen most often. A well-written NAD+ standing order prevents most of those calls by giving nurses clear parameters for managing the expected side effect profile.
Protocol 2: Patient Screening & Pre-Infusion Assessment
The intake form and pre-infusion assessment are the medical director's primary tool for patient protection at the point of care. They are also among the most consistently under-designed documents in IV therapy practices. An intake form that asks for name, allergies, and emergency contact is not a clinical screening document.
A compliant pre-infusion screening protocol must capture the information needed to apply every contraindication in every standing order you have. That means the screening document is always downstream of the standing orders — you design the standing orders first, then build the intake form to capture what those orders require.
- Medical history fields required: Renal disease or impairment (CKD, dialysis), cardiovascular disease (CHF, arrhythmia, recent MI), G6PD deficiency (required before offering high-dose C), active pregnancy or breastfeeding, kidney stone history (for vitamin C offerings), current medications including anticoagulants and NSAIDs (for Toradol), active infections, recent surgery.
- Allergy documentation: Specific allergy to any ingredient in any offered formulation — including allergy to sulfites (present in some B-complex formulations), thiamine (rare but real), and NSAIDS for Toradol. "NKDA" is insufficient if the patient doesn't know what's in the drip.
- Vital signs pre-infusion: Blood pressure, heart rate, oxygen saturation minimum. The standing order must specify the vital sign thresholds that require director contact before proceeding — e.g., SBP >160, HR >100 at rest, SpO2 <95%.
- Hydration status assessment: Basic clinical assessment for dehydration versus volume overload — particularly relevant for high-volume hydration drips in patients with cardiac history.
- Signed informed consent: A separate consent document — not buried in the intake form — that describes the specific drip being administered, its potential adverse effects, and the patient's right to stop the infusion at any time.
G6PD deficiency affects approximately 400 million people worldwide and is significantly underdiagnosed — many patients don't know they have it. High-dose IV vitamin C in a patient with G6PD deficiency can trigger a potentially life-threatening hemolytic anemia. The standard of care for doses above 15–25g is G6PD testing before initiation. If your intake doesn't ask, and your standing order doesn't require it, this is a documented compliance failure.
Protocol 3: Emergency & Adverse Event Protocols
Every IV therapy practice must have documented emergency protocols. Not a reference to "call 911" — a specific, step-by-step response protocol for each adverse event category that nursing staff will actually encounter. The goal is that any nurse, even one new to the practice, can respond correctly to an adverse event without waiting for direction.
| Adverse Event | Severity | Immediate Response Protocol Must Cover | Director Contact Threshold |
|---|---|---|---|
| Infiltration / extravasation | Low | Stop infusion, remove IV, elevate extremity, assess site for blanching (vesicant risk), document site assessment, warm compress per formulation, restart in alternate site | Any signs of tissue damage, vesicant infiltration, or patient distress |
| Vasovagal response (syncope / presyncope) | Moderate | Lower patient to supine, slow or pause infusion, check vitals, provide NS bolus per protocol, assess LOC, document event timeline | Loss of consciousness >1 minute, failure to resolve within 5 minutes, or abnormal vitals on recovery |
| Mild allergic reaction (urticaria, pruritus, localized flush) | Moderate | Stop infusion immediately, assess airway, administer diphenhydramine IM or PO per standing order, monitor vitals q5 min, document reaction onset and symptoms | Immediately upon stopping infusion — director must be notified of any allergic reaction |
| Anaphylaxis | Critical | Call 911 first, administer epinephrine IM (0.3mg 1:1000) lateral thigh, lay patient supine with legs elevated, begin CPR if indicated, designate staff member to wait for EMS outside, assign second nurse to monitor patient, do not leave patient alone | Call 911 before calling director — EMS first, director notification concurrent |
| Fluid overload symptoms (dyspnea, rales, peripheral edema acutely worsening) | Critical | Stop infusion immediately, sit patient upright, assess vitals and breath sounds, call 911 for respiratory distress, document infusion volume administered and rate | Immediately — any respiratory symptom during IV fluid administration is a director-contact event |
| NAD+ adverse reaction (chest tightness, palpitations, severe nausea) | Moderate | Slow infusion rate to minimum, assess vitals, have patient describe symptoms precisely, document onset in relation to rate, contact director if chest tightness does not resolve with rate reduction within 10 minutes | Chest tightness not resolving with rate reduction; any cardiac symptoms; SpO2 drop |
| Phlebitis (site warmth, erythema, tenderness along vein) | Low | Discontinue infusion at that site, remove catheter, apply warm compress, document site assessment (1–4 INS phlebitis scale), monitor for progression, do not restart at adjacent site without assessment | Grade 3–4 phlebitis (severe pain, palpable cord, purulent drainage) |
Epinephrine 1mg/mL (1:1000) for IM injection must be physically present in the IV lounge — not at a pharmacy around the corner. Anaphylaxis can progress from mild urticaria to cardiovascular collapse in minutes. A practice that does not have epinephrine and a documented protocol for its administration is operating below the minimum standard of care for a facility administering IV infusions. The epinephrine must be checked for expiration at minimum monthly, with documented inspection records.
Protocol 4: Scope of Practice Boundaries for Nursing Staff
The standing orders and emergency protocols define what nursing staff can do. The scope of practice boundary document defines when they must stop and call. This is a separate, explicit document — and it's often the missing piece in practices that have standing orders but still have director "on-call" events that shouldn't require director involvement.
A scope boundary protocol for IV therapy nursing staff should specify:
- What RNs can initiate independently: Any drip with completed screening, no contraindications flagged, and vital signs within the specified parameters in the standing order.
- What requires director contact before proceeding: Patient with any relative contraindication; vital signs outside standing order parameters; patient who reports a new symptom not documented on intake; patient whose medical history was disclosed verbally but not captured in writing; any request for a drip not on the standing order menu.
- What requires director contact during infusion: Any adverse event above "expected" per the drip standing order; vital sign change outside monitoring parameters; patient who wants to stop and is experiencing symptoms (versus patient who simply wants to leave).
- What triggers 911 before director contact: Anaphylaxis, loss of consciousness >1 minute, respiratory distress, chest pain with cardiac risk factors, new onset neurological symptoms. EMS first. Director concurrent or after.
- Documentation standards: What must be documented for every infusion (vitals at start and end, drip administered, volume, lot number, any events during infusion), and where (EMR, paper chart, or the practice's designated system).
What a Real IV Medical Director Relationship Looks Like
The compliance gap that creates the most liability exposure for IV therapy practices isn't usually missing paperwork — it's a medical director relationship that is nominal on paper and absent in practice. The director signed the standing orders. The director has never visited the facility. The director couldn't name the formulations currently being administered. That is not oversight. It is a signature on a document.
The Arizona Medical Board and the Board of Nursing both view medical director oversight as an active, ongoing relationship — not a one-time document signing. The specific enforcement actions against IV therapy practices have consistently cited the same pattern: a director whose involvement ended at the standing order signature and who had no awareness of what was actually happening at the point of care.
The directorship agreement deserves specific attention. This is a written contract between the director and the practice that specifies exactly what the director is responsible for, what the practice is responsible for, how the director is compensated, and what happens if either party needs to end the relationship. A handshake arrangement or an email thread is not a directorship agreement. A practice operating under a verbal agreement with a director is operating without meaningful protection if that director relationship ends abruptly.
When you sign a standing order for an IV therapy practice, you are authorizing nurses to administer medications to patients based on your clinical judgment, embedded in that document. If the order is vague, if the practice administers something not covered by the order, or if an adverse event occurs that the order didn't anticipate and address — your signature is on the document. Active oversight is not just ethical; it is the practical protection against liability exposure that a meaningful directorship provides. A practice you've visited, whose staff you've met, whose protocols you've reviewed recently, and whose adverse events you're aware of is a practice you can defend. One you haven't is a document you signed.